China NMPA Drug Inspection - Yangchun Bafang Traditional Chinese Medicine Pieces Co., Ltd. - Poria

This report, issued by the Guangdong Provincial Drug Administration on March 5, 2020 (Announcement No. 21), details the third batch of quality inspections for medications used in COVID-19 prevention and control. The inspections targeted 114 batches of 43 drug varieties across 9 manufacturing plants, 60 distributors, and one medical institution. Key participating companies included Foshan Shouxin Pharmaceutical Co., Ltd., Guangzhou Baiyunshan Pharmaceutical Group, Shijiazhuang Yiling Pharmaceutical Co., Ltd., and various branches of the Sinopharm Group. The scope of the testing included essential medicines such as Amoxicillin, Antiviral Oral Solutions, Isatis Root Granules, and Lianhua Qingwen Capsules. Following rigorous testing, the administration confirmed that all 114 batches complied with the required safety and quality standards. No violations or substandard products were reported. These inspections were carried out under the regulatory framework of the National Medical Products Administration (NMPA) and followed guidelines set by the Chinese Pharmacopoeia (2010 and 2015 editions). Because all samples met the legal requirements, no punitive or corrective actions were necessary. The provincial authorities will continue to perform comprehensive post-market supervision and random sampling to maintain the integrity of the pharmaceutical supply chain during the pandemic period.